As reported by transcript (https://transkript.de/news/qiagen-mitgruender-investiert-in-priavoid.html) the company Priavoid based in
Jülich (Germany) (https://priavoid.com/) has successfully completed phase I using special peptides for treatment of Alzheimer's disease.
The approach is based on D-enantiomeric peptides, that mirror the naturally occurring peptides based on L-amino acids.
The active ingredient directly destroys toxic β-amyloid oligomers and breaks them down into the harmless β-amyloid
monomers without the involvement of the immune system.
If you are interested in peptides consisting of D-amino acids, you are welcome to contact Genaxxon: firstname.lastname@example.org or just have a look at: https://www.genaxxon.com/shop-all-products/peptide-proteins/ or https://www.genaxxon.com/shop-all-products/peptide-proteins/alzheimer-peptide/ to get an idea about the vast range of peptides Genaxxon bioscience can offer.